Joe Milata

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Geert D’Haens, Marla C. Dubinsky, Taku Kobayashi et al. · New England Journal of Medicine · 2023 · 317 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +17

Comparison of the Efficacy and Safety of Oritavancin Front-Loaded Dosing Regimens to Daily Dosing: an Analysis of the SIMPLIFI Trial

Lala M. Dunbar, Joe Milata, Ty McClure et al. · Antimicrobial Agents and Chemotherapy · 2011 · 64 citations

Medicine, Pharmacokinetics, Pharmacology +17

Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

Bruce E. Sands, Geert D’Haens, David B. Clemow et al. · Inflammatory Bowel Diseases · 2024 · 53 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

Bruce E. Sands, Geert D’Haens, David B. Clemow et al. · Inflammatory Bowel Diseases · 2024 · 25 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +17

867e: EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY

Marla C. Dubinsky, Peter M. Irving, Xingyuan Li et al. · Gastroenterology · 2022 · 10 citations

Medicine, Clinical Sciences, Pharmacotherapy +13